On December 4, 2018 LineaRx, Inc., the biotherapeutics company based on the use of large-scale production of gene-sized DNA by Polymerase Chain Reaction ("PCR") and dedicated to revolutionizing biotherapeutics for the masses in affordability, availability, time-to-market, and reducing the risk associated with virally mediated therapy, and a wholly-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), reported that it will host an Analyst Day via webinar on Thursday, December 6, 2018 at 12 p.m. to 1:30 p.m. EST (Press release, Applied DNA Sciences, DEC 4, 2018, View Source [SID1234531906]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the 90-minute technical presentation Dr. James Hayward, CEO of LineaRx, Dr. Michael Hogan, Vice President of Life Sciences and Dr. Stephen Hughes, Director of DNA Programs will address:
Collaborative data on PCR-produced anti-cancer (anti-telomerase) vaccine show immunogenicity in mice,
Licensed CAR-T Therapy; partner data to be presented show efficacy in animals and humans when delivered via plasmid and virus, which bodes well for the prospect of similar efficacy of corresponding linear construct under development,
The concept for adoptive cell therapies without delay: "Networked DNA-producing PCR devices informed by Artificial Intelligence and located in hospitals operating under cGMP", and,
Proprietary IP should enable high levels of gene expression, self-transducing genes, transiently expressed genes without genomic integration; the sum of which should generate localized, in-hospital production of more effective adoptive cell therapies, faster, with a higher Therapeutic Index and a simpler mode of manufacture.
LineaRx Webinar Information
To participate in the LineaRx webinar, please follow the instructions below. Management will take questions from select invitees in the Q&A portion of the event.
To Participate:
Participant Toll Free: 1-844-887-9402
Participant Toll: 1-412-317-6798
Please ask to be joined to the LineaRx webinar
Live webcast: View Source
Replay (available 1 hour following the conclusion of the live call through December 13, 2018):
Participant Toll Free: 1-877-344-7529
Participant Toll: 1-412-317-0088
Participant Passcode: 10126911
Webcast replay: View Source
"This Analyst Day webinar serves as an excellent platform from which to build awareness for LineaRx’s competitive advantages and user benefits to the biotherapeutics industry at large. Anyone currently utilizing plasmid DNA and/or virus to transduce cells, in the DNA/RNA vaccine space, involved in CRISPR as well as, CAR-T Therapy could benefit greatly from our technology," stated Dr. Hayward.